2. Search Result
Search Result
Pathways Recommended: Stem Cell/Wnt Cell Cycle/DNA Damage
Results for "

human cancer cells

" in MedChemExpress (MCE) Product Catalog:

1516

Inhibitors & Agonists

17

Screening Libraries

23

Fluorescent Dyes

17

Biochemical Assay Reagents

57

Peptides

1

MCE Kits

188

Inhibitory Antibodies

380

Natural
Products

1

Recombinant Proteins

31

Isotope-Labeled Compounds

9

Click Chemistry

29

Oligonucleotides

3

GMP Molecules

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P991015
    Pasritamig

    JNJ-78278343; KLCB-245

    		 CD3 Cancer
    Pasritamig (JNJ-78278343; KLCB-245) is a bispecific T-cell engager (BiTE) that targets the complex of human kallikrein KLK2 and CD3 receptor. Pasritamig redirects the cytotoxicity of T cells to KLK2-expressing tumor cells and induces T cell-mediated lysis of KLK2-expressing prostate cancer cells. Administered via subcutaneous injection, subcutaneous infusion or intravenous infusion, Pasritamig exhibits antitumor activity against metastatic castration-resistant prostate cancer. Pasritamig has a safety profile with an extremely low incidence of cytokine release syndrome and can be safely administered in an outpatient setting. Pasritamig is applicable to the research of metastatic castration-resistant prostate cancer .
    Pasritamig
  • HY-164992
    Trastuzumab vedotin
    2 Publications Verification

    MRG002; Trastuzumab MMAE

    		 Antibody-Drug Conjugates (ADCs) EGFR Microtubule/Tubulin Cancer
    Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .
    Trastuzumab vedotin
  • HY-156617A
    (αR)-Cyclopropaneacetamide-Exatecan

    SHR169265

    		 ADC Payload Topoisomerase Cancer
    (αR)-Cyclopropaneacetamide-Exatecan (SHR169265) is a DNA Topoisomerase I inhibitor with enhanced membrane permeability (with an IC50 of 1.34 μM against the human DNA Topoisomerase I). (αR)-Cyclopropaneacetamide-Exatecan exerts cytotoxic effects by inhibiting the enzymatic activity of Topoisomerase I, and this anticancer effect is independent of the expression level of HER2. (αR)-Cyclopropaneacetamide-Exatecan is an ADC Cytotoxin derived from Exatecan (HY-13631), which can be used in research related to advanced cancers such as breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer .
    (αR)-Cyclopropaneacetamide-Exatecan
  • HY-115385
    Lumichrome
    2 Publications Verification

    		 Apoptosis MDM-2/p53 Akt β-catenin Nuclear Factor of activated T Cells (NFAT) NF-κB ERK p38 MAPK Metabolic Disease Cancer
    Lumichrome, a photodegradation product of Riboflavin, is an endogenous compound in humans. Lumichrome inhibits human lung cancer cell growth and induces apoptosis via a p53-dependent mechanism. Lumichrom is the inhibitor for AKT/β-catenin signaling pathway .
    Lumichrome
  • HY-P9964
    Necitumumab

    11F8; IMC-11F8; LY3012211

    		 EGFR Cancer
    Necitumumab (11F8; IMC-11F8; LY3012211) is a human IgG monoclonal antibody directed against EGFR. Necitumumab binds to the EGF binding site of EGFR, blocks ligand binding, neutralizes ligand-induced EGFR phosphorylation and downstream signaling, induces EGFR internalization and degradation, and mediates antibody-dependent cellular cytotoxicity (ADCC) in EGFR-expressing cells. Necitumumab enhances antitumour activity in combination with Gemcitabine (HY-17026) and Cisplatin (HY-17394) in murine non-small-cell lung cancer xenograft models. Necitumumab can be used in research on cancers such as non-small cell lung cancer and colorectal cancer .
    Necitumumab
  • HY-133668
    Monoethyl phthalate

    		Drug Metabolite Cytochrome P450 PPAR Endocrinology Cancer
    Monoethyl phthalate is an orally active PDX-1 activator and the major hydrolytic metabolite of Diethyl phthalate (HY-Y0284) in vivo, with reproductive toxicity. Monoethyl phthalate targets aromatase (aromatase/CYP19A1) and PPAR to induce cell proliferation. The plasma protein binding rate of Monoethyl phthalate in rats and humans is lower than that of Diethyl phthalate. It exhibits significant enterohepatic circulation in rats and mainly accumulates in liver tissues. Monoethyl phthalate shows no estrogenic activity in estrogen-dependent human breast cancer cells. Monoethyl phthalate can be used in studies of reproductive toxicity and related environmental endocrine disruption mechanisms .
    Monoethyl phthalate
  • HY-110042
    CCT018159

    		HSP Apoptosis CDK PERK Metabolic Disease Inflammation/Immunology Cancer
    CCT018159 is an ATP-competitive HSP90β inhibitor, with an IC50 of 3.2 μM against human HSP90β ATPase and 6.6 μM against yeast HSP90β ATPase. CCT018159 induces cell cycle arrest and apoptosis in tumor cells, and inhibits invasion and angiogenesis. CCT018159 is applicable to cancer-related research .
    CCT018159
  • HY-N11908
    α-Santalol

    cis-α-Santalol

    		 Akt Survivin Apoptosis Caspase PARP Metabolic Disease Cancer
    α-Santalol (cis-α-Santalol), a naturally occurring sesquiterpene, is an orally active anticancer agent and apoptosis inducer. α-Santalol activates caspase-3 to drive apoptotic processes. >α-Santalol induces apoptosis, decreases cell viability, and causes PARP cleavage in human prostate cancer cells. α-santalol inhibits Akt/Survivin pathway to induce cell death. α-Santalol can be used for the research of prostate cancer and diabetes mellitus .
    α-Santalol
  • HY-P991567
    VX5

    VX5/5261

    		 CXCR Inflammation/Immunology Cancer
    VX5 (VX5/5261) is a humanized IgG1κ monoclonal antibody inhibitor targeting BCA-1/CXCL13. VX5 significantly inhibits human CXCL13-mediated internalization of CXCR5, blocks both human and mouse CXCL13-dependent B-cells chemotaxis and migration. VX5 can be used to study autoimmune diseases like multiple sclerosis and arthritis, and cancers like gastric lymphomas and colon cancer .
    VX5
  • HY-156649
    Vorbipiprant

    CR6086

    		 Prostaglandin Receptor Interleukin Related MMP PD-1/PD-L1 Cardiovascular Disease Inflammation/Immunology Cancer
    Vorbipiprant (CR6086) is an orally active EP4 receptor antagonist with high selectivity for the human EP4 receptor (Ki: 16.6 nM). Vorbipiprant has immunomodulatory, anti-inflammatory, antitumor, and anti-angiogenic activities. Vorbipiprant can inhibit the expression of multiple pro-inflammatory cytokines and the activation of immune cells, and convert "cold" tumors unresponsive to immune checkpoint inhibitors into "hot" tumors. Vorbipiprant is used in the research of diseases such as rheumatoid arthritis and colon cancer .
    Vorbipiprant
  • HY-N6002
    3'-Hydroxypterostilbene
    1 Publications Verification

    		 Apoptosis Autophagy Cancer
    3'-Hydroxypterostilbene is a Pterostilbene (HY-N0828) analogue. 3'-Hydroxypterostilbene inhibits the growth of COLO 205, HCT-116 and HT-29 cells with IC50s of 9.0, 40.2 and 70.9 μM, respectively. 3'-Hydroxypterostilbene significantly down-regulates PI3K/Akt and MAPKs signaling pathways and effectively inhibits the growth of human colon cancer cells by inducing apoptosis and autophagy. 3'-Hydroxypterostilbene can be used for the research of cancer .
    3'-Hydroxypterostilbene
  • HY-12854
    Imetelstat

    GRN163L

    		 Telomerase Apoptosis Cardiovascular Disease Cancer
    Imetelstat (GRN163L) is a 13-mer oligonucleotide and competitive Telomerase inhibitor. Imetelstat binds with high affinity to the template region of the RNA component of human telomerase. Imetelstat induces Apoptosis. Imetelstat is capable of selectively eliminating myelofibrosis hematopoietic stem cells. Imetelstat leads to the loss of a cancer cell's ability to maintain telomere length, resulting in the inhibition of cell proliferation .
    Imetelstat
  • HY-P5098
    E(c(RGDfK))2

    		Integrin Neurological Disease Cancer
    E (c (RGDfK)) 2 is a αvβ3 integrin ligand and tumor-targeting agent. E (c (RGDfK)) 2 binds to αvβ3 integrin, mediates receptor-mediated endocytosis of conjugated payloads, and inhibits integrin-dependent cell adhesion to fibrinogen. E (c (RGDfK)) 2 inhibits the proliferation of cancer cells and endothelial cells. E (c (RGDfK)) 2 preferentially accumulates in orthotopic mouse breast tumors and human ovarian cancer xenograft tumors. E (c (RGDfK)) 2 can be used in research related to glioblastoma, lung cancer, breast adenocarcinoma and ovarian cancer .
    E(c(RGDfK))2
  • HY-176497
    GW273297X

    G297X

    		 Cytochrome P450 Metabolic Disease Cancer
    GW273297X is a selective CYP27A1 inhibitor. GW273297X blocks 27-hydroxycholesterol biosynthesis and sterol product formation in human macrophages. GW273297X reduces cancer cells colonization by inhibiting pro-metastatic effects of 27-hydroxycholesterol. GW273297X can be used for the researches of cancer and metabolic disease, such as breast cancer .
    GW273297X
  • HY-169259
    HDAC9-IN-1

    		HDAC DNA/RNA Synthesis Reactive Oxygen Species (ROS) Apoptosis Caspase p38 MAPK Cancer
    HDAC9-IN-1 is a selective class IIa HDAC inhibitor that binds to HDAC9 with an IC50 of 40 nM. HDAC9-IN-1 potently inhibits HDACs 4 and 7 while showing weak activity against HDAC6 (IC50 values: 180 nM (HDAC4), 190 nM (HDAC7), 970 nM (HDAC6)). HDAC9-IN-1 significantly inhibits several human cancer cells, induces apoptosis and DNA damage in human cancer cells, and modulates caspase-related proteins and p38 in human cancer cells. HDAC9-IN-1 can be used for the research of oral cancer, breast cancer, gastric cancer .
    HDAC9-IN-1
  • HY-N8572
    3',4'-Dimethoxyflavone
    1 Publications Verification

    		 PARP Reactive Oxygen Species (ROS) Aryl Hydrocarbon Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    3',4'-Dimethoxyflavone is a lipophilic flavone, can be isolated from the leaves of Primula veris. 3',4'-Dimethoxyflavone can reduce the synthesis and accumulation of PARP and protect cortical neurones against cell death induced by Parthanatos. 3',4'-Dimethoxyflavone is also an aryl hydrocarbon receptor antagonist in human breast cancer cells. 3',4'-Dimethoxyflavone can promote the proliferation of human hematopoietic stem cells. 3',4'-Dimethoxyflavone has various biological activities, including antioxidant, anti-cancer, anti-inflammatory, anti-atherogenic, hypolipidaemic, and neuroprotective or neurotrophic effects .
    3',4'-Dimethoxyflavone
  • HY-121382
    Gypsogenin

    		Cholinesterase (ChE) Apoptosis Necroptosis Neurological Disease Cancer
    Gypsogenin is a selective mixed-type BChE inhibitor (Ki=19.99 μM) that also exhibits significant cytotoxicity against various human cancer cell lines. Gypsogenin inhibits tumor growth by inducing cell cycle arrest and triggering apoptosis. Gypsogenin displays antibacterial activity against bacteria such as Bacillus subtilis and Bacillus thuringiensis, and often serves as a key parent nucleus for the synthesis of anticancer compounds. Gypsogenin is widely used in research on Alzheimer's disease and various cancers including colon cancer, melanoma, and leukemia .
    Gypsogenin
  • HY-125035
    LCH-7749944
    5 Publications Verification

    GNF-PF-2356

    		 PAK Apoptosis Cancer
    LCH-7749944 (GNF-PF-2356) is a potent PAK4 inhibitor with an IC50 of 14.93 μM. LCH-7749944 effectively suppresses the proliferation of human gastric cancer cells through downregulation of PAK4/c-Src/EGFR/cyclin D1 pathway and induces apoptosis .
    LCH-7749944
  • HY-143904
    PROTAC TTK degrader-1

    		PROTACs Mps1 Cancer
    PROTAC TTK degrader-1 is a potent TTK (threonine tyrosine kinase) PROTAC degrader, with DC50 values of 1.7 and 5.8 nM in COLO-205 and HCT-116 cell, respectively. PROTAC TTK degrader-1 exhibits target degradation and anticancer efficacy in a xenograft mouse model of COLO-205 human colorectal cancer cells .
    PROTAC TTK degrader-1
  • HY-P991196
    Anti-CD24 Antibody (SWA11)

    		Transmembrane Glycoprotein Cancer
    Anti-CD24 Antibody (SWA11) is a human IgG1 monoclonal antibody targeting CD24, with high affinity and specificity for CD24-expressing tumor cells. Anti-CD24 Antibody (SWA11) triggers endocytosis, alters STAT3-dependent gene expression, regulates Src phosphorylation, and blocks CD24-mediated signaling pathways. Anti-CD24 Antibody (SWA11) is applicable to cancer-related research such as lung cancer and ovarian cancer. Recommended isotype control: Human IgG1 kappa, Isotype Control (HY-P99001) .
    Anti-CD24 Antibody (SWA11)
  • HY-W115529
    Geranic acid

    Geranate; NSC 229335; GAGE

    		 Environmental Pollutants Fungal Tyrosinase Infection Cancer
    Geranic acid (Geranate) acts as a tyrosinase inhibitor and antifungal agent, with an IC50 value of 0.14-2.3 mM against mushroom tyrosinase. Geranic acid reduces the viability of human pancreatic cancer cells and B-lymphoma cells. Geranic acid inhibits mycelial growth of the maize pathogens Colletotrichum graminicola and Fusarium graminearum. Geranic acid is applicable to research related to fungal infections, pancreatic cancer and B-lymphoma .
    Geranic acid
  • HY-131344
    mTOR inhibitor-8

    		mTOR Autophagy Cancer
    mTOR inhibitor-8 is an mTOR inhibitor and autophagy inducer. mTOR inhibitor-8 inhibits the activity of mTOR via FKBP12 and induces autophagy of A549 human lung cancer cells .
    mTOR inhibitor-8
  • HY-149056
    GNE-6893

    		MAP4K Interleukin Related Cancer
    GNE-6893 is an orally active, selective HPK1 inhibitor with a Ki < 0.02 nM. GNE-6893 enhances T cell receptor signaling in primary human T cells. GNE-6893 increases IL2 production in stimulated primary human T cells. GNE-6893 can be used for the research of chronic refractory cancers .
    GNE-6893
  • HY-P990953
    Zubotamig

    Gen1047

    		 CD3 Cancer
    Zubotamig (Gen1047) is an CD3E/VTCN1-targeting Ig(G1 -κ_G1 -λ2) type chimeric human antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zubotamig induces T-cell mediated cytotoxicity of B7H4-positive tumor cells, triggers T-cell activation, and induces cytokine release from T cells in the presence of B7H4-expressing tumor cells. Zubotamig demonstrates antitumor activity in mouse patient-derived xenograft (PDX) models. Zubotamig can be used for the research of solid cancers (including breast, ovarian and lung cancer) .
    Zubotamig
  • HY-P991358
    XOMA-213

    LFA-102; X213

    		 Estrogen Receptor/ERR STAT Akt Cancer
    XOMA-213 (LFA-102; X213) is a human monoclonal antibody (mAb) targeting the prolactin receptor (PRLR), with a Kd value of 2 nM against the human target. XOMA-213 blocks PRL-induced cell proliferation and inhibits the activation of multiple PRLR ligands, including PRL and human growth hormone (hGH). XOMA-213 suppresses PRL-induced phosphorylation of Stat5, Akt and ERK1/2 in cells. XOMA-213 induces tumor regression, delays disease progression, and inhibits PRLR signaling as well as tumor growth. XOMA-213 can be used in research related to breast cancer .
    XOMA-213
  • HY-N0855
    Alisol G

    Alisol-G; 25-Anhydroalisol A

    		 Carboxylesterase (CES) Bacterial HBV Infection Cancer
    Alisol G (25-Anhydroalisol A) is a human carboxylesterase 2 (hCES2) inhibitor with an IC50 of 3.85 μM. Alisol G exhibits cytotoxic activity against human cancer cells, antibacterial activity against Gram-positive strains, and anti-hepatitis B virus activity. Alisol G can be used in research related to lung cancer, breast cancer, prostate cancer, bacterial infections, and HBV infections .
    Alisol G
  • HY-P99516
    Vulinacimab

    HLX-06

    		 VEGFR Cancer
    Vulinacimab (HLX-06) is a human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2). Vulinacimab specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. Vulinacimab can be used for the research of solid tumors and non-small cell lung cancer .
    Vulinacimab
  • HY-106777
    Cyclopentenylcytosine
    1 Publications Verification

    CPEC; NSC 375575

    		 DNA/RNA Synthesis Nucleoside Antimetabolite/Analog Apoptosis Necroptosis Influenza Virus HSV Infection Cancer
    Cyclopentenylcytosine (CPEC), a carbocyclic nucleoside analog of cytosine, is a potent inhibitor of CTP synthetase and causes depletion of CTP and dCTP pools. Cyclopentenylcytosine shows broad-spectrum (both DNA and RNA viruses) antiviral activity. Cyclopentenyl cytosine increases Gemcitabine (HY-17026) radiosensitisation in human pancreatic cancer cells. Cyclopentenylcytosine shows effective antiviral activity in the Ad5/NZW rabbit ocular replication model and shows anti-tumor activity in various tumor xenografts model. Cyclopentenylcytosine can be used for the study of infection and cancer .
    Cyclopentenylcytosine
  • HY-N8619
    Minimolide F
    1 Publications Verification

    		 Others Cancer
    Minimolide F is a sesquiterpene lactone. Minimolide F has inhibitory activity against human nasopharyngeal cancer cells. Minimolide F can be used for the research of cancer .
    Minimolide F
  • HY-108999A
    Crisnatol
    1 Publications Verification

    BWA770U

    		 DNA/RNA Synthesis Cancer
    Crisnatol (BWA770U) is an orally active and anticancer agent, and a member of the arylmethylaminopropanediol class of DNA intercalators. Crisnatol shows in vitro cytotoxicity against human breast cancer cells, but not normal human skin fibroblasts .
    Crisnatol
  • HY-W854385
    Sialyl Lewis A

    SLeA

    		 Biochemical Assay Reagents E-Selectin Cancer
    Sialyl Lewis A (SLeA) is a tumor-associated carbohydrate antigen, also known as carbohydrate antigen 19-9 (CA19-9), that binds to E-selectin (ELAM-1) and selectins to mediate cell-endothelium adhesion. Sialyl Lewis A promotes cancer cell-vascular endothelium adhesion, and its surface presence correlates with increased tumorigenicity and invasiveness in cancer cells. Sialyl Lewis A shows elevated expression in human adenocarcinomas of the colon, pancreas, and stomach, with expression levels linked to tumor progression and poor prognosis in colorectal and gastric carcinomas. Sialyl Lewis A can be used for the research of cancers, such as colon, pancreas, stomach, and squamous lung cancer .
    Sialyl Lewis A
  • HY-121352
    Kibdelone C

    		Drug Derivative Cancer
    Kibdelone C is a hexacyclic tetrahydroxanthone natural product and anticancer agent with sub-nanomolar GI50 activity against human SR leukemia and SN12C renal carcinoma cell lines. Kibdelone C disrupts the actin cytoskeleton in human cancer cells, leading to cell contraction and actin stress fiber formation, without direct actin binding, actin polymerization effects, topoisomerase I/II inhibition, or DNA binding. Kibdelone C can be used for the research of leukemia, and renal cell carcinoma .
    Kibdelone C
  • HY-149372
    HDAC6-IN-17

    		HDAC Cancer
    HDAC6-IN-17 (compound 5b) is a potent HDAC6 inhibitor with IC50 values of 150 nM, 1400 nM, and 2300 nM for HDAC6, HDAC8, and HDAC4, respectively. HDAC6-IN-17 has cytotoxic activity on human cancer cell lines. HDAC6-IN-17 can be used in research of cancer .
    HDAC6-IN-17
  • HY-143905
    PROTAC TTK degrader-2

    		PROTACs Mps1 Cancer
    PROTAC TTK degrader-2 is a potent TTK (threonine tyrosine kinase) PROTAC degrader, with DC50 values of 3.1 and 12.4 nM in COLO-205 and HCT-116 cell, respectively. PROTAC TTK degrader-2 exhibits target degradation and anticancer efficacy in a xenograft mouse model of COLO-205 human colorectal cancer cells .
    PROTAC TTK degrader-2
  • HY-177275
    c-Kit Receptor modulator-1

    		c-Kit Cancer
    c-Kit Receptor modulator-1 (Compound #22) is a c-Kit Receptor modulator. c-Kit Receptor modulator-1 can be used for malignant cancers such as canine mastocytoma, human gastrointestinal stromal tumor and small cell lung cancer research .
    c-Kit Receptor modulator-1
  • HY-N8572R
    3',4'-Dimethoxyflavone (Standard)

    		Reference Standards PARP Reactive Oxygen Species (ROS) Aryl Hydrocarbon Receptor Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
    3',4'-Dimethoxyflavone is a lipophilic flavone, can be isolated from the leaves of Primula veris. 3',4'-Dimethoxyflavone can reduce the synthesis and accumulation of PARP and protect cortical neurones against cell death induced by Parthanatos. 3',4'-Dimethoxyflavone is also an aryl hydrocarbon receptor antagonist in human breast cancer cells. 3',4'-Dimethoxyflavone can promote the proliferation of human hematopoietic stem cells. 3',4'-Dimethoxyflavone has various biological activities, including antioxidant, anti-cancer, anti-inflammatory, anti-atherogenic, hypolipidaemic, and neuroprotective or neurotrophic effects .
    3',4'-Dimethoxyflavone (Standard)
  • HY-N3446
    IVHD-valtrate

    		Apoptosis Cancer
    IVHD-valtrate, an active Valeriana jatamansi derivative, is against human ovarian cancer cells in vitro and in vivo. IVHD-valtrate induces cancer cells apoptosis and arrests the ovarian cancer cells in the G2/M phase. IVHD-valtrate has the potential to be a novel chemotherapeutic agent for the human ovarian cancer research .
    IVHD-valtrate
  • HY-108999
    Crisnatol mesylate

    BWA770U mesylate

    		 DNA/RNA Synthesis Cancer
    Crisnatol (BWA770U) mesylate is an orally active and anticancer agent, and a member of the arylmethylaminopropanediol class of DNA intercalators. Crisnatol mesylate shows in vitro cytotoxicity against human breast cancer cells, but not normal human skin fibroblasts .
    Crisnatol mesylate
  • HY-116639
    Javanicin

    		Bacterial Infection Cancer
    Javanicin is an antibacterial agent with certain antibacterial activity against pathogenic bacteria such as Bacillus megaterium, Staphylococcus aureus, Salmonella typhi, and Escherichia coli. Javanicin has weak cytotoxicity against the human lung cancer cell line .
    Javanicin
  • HY-108999AR
    Crisnatol (Standard)

    BWA770U (Standard)

    		 DNA/RNA Synthesis Reference Standards Cancer
    Crisnatol (Standard) is the analytical standard of Crisnatol. This product is intended for research and analytical applications. Crisnatol (BWA770U) is an orally active and anticancer agent, and a member of the arylmethylaminopropanediol class of DNA intercalators. Crisnatol shows in vitro cytotoxicity against human breast cancer cells, but not normal human skin fibroblasts .
    Crisnatol (Standard)
  • HY-W087006
    p-Hydroxyphenylacetone

    		Androgen Receptor Cancer
    p-Hydroxyphenylacetone, a Raspberry ketone (HY-N1426) derivative, is an androgen receptor (AR) antagonist with an IC50 of 420 μM in MDA-kb2 human breast cancer cells. p-Hydroxyphenylacetone can be used for breast cancer research .
    p-Hydroxyphenylacetone
  • HY-116473
    CFM-1

    		APC Cancer
    CFM-1 is a small molecule antagonist of CARP-1/APC-2 binding with an EC50 value of 4.1 μM. CFM-1 induces G2M cell cycle arrest and suppresses viabilities of human breast cancer cells .
    CFM-1
  • HY-147915
    Benz-AP

    		Carboxylesterase (CES) Reactive Oxygen Species (ROS) Cancer
    Benz-AP is a potent photosensitizer. Benz-AP produces singlet oxygen, with a negative correlation with hCES2 (Human carboxylesterase 2) activity. Benz-AP displays a higher photocytotoxicity potency in cancer cells under low hCES2 environments. Upon TPE (Two-photon excitation), Benz-AP produces ROS and kills cancer cells and tumor spheroids .
    Benz-AP
  • HY-126803
    Saquayamycin B

    		Antibiotic Infection Cancer
    Saquayamycin B (compound 3) is a new angucycline antibiotic. Saquayamycin B has antitumor activities against a human lung (H-460) and a human breast cancer cell line (MCF-7) with GI50 values of 12.2 and 15.2 µM respectively .
    Saquayamycin B
  • HY-115385R
    Lumichrome (Standard)

    		Reference Standards Apoptosis MDM-2/p53 Akt β-catenin Nuclear Factor of activated T Cells (NFAT) NF-κB ERK p38 MAPK Metabolic Disease Cancer
    Lumichrome (Standard) is the analytical standard of Lumichrome. This product is intended for research and analytical applications. Lumichrome, a photodegradation product of Riboflavin, is an endogenous compound in humans. Lumichrome inhibits human lung cancer cell growth and induces apoptosis via a p53-dependent mechanism. Lumichrom is the inhibitor for AKT/β-catenin signaling pathway. Lumichrom is the inhibitor for AKT/β-catenin signaling pathway .
    Lumichrome (Standard)
  • HY-182397
    ZX-J-19L

    		Cyclophilin Cancer
    ZX-J-19L is a CyPJ inhibitor with inhibitory activity against a variety of tumor cell lines. ZX-J-19L inhibits the growth of human liver cancer cells, human breast cancer cells, ovarian cancer cells and prostate cancer cells in vitro. ZX-J-19L can be used for tumor research .
    ZX-J-19L
  • HY-N18186
    Neojiangyouaconitine

    		Others Cancer
    Neojiangyouaconitine is a diterpenoid alkaloid cytotoxin isolated from Aconitum soongaricum var. pubescens. Neojiangyouaconitine exhibits cytotoxic activity against human breast cancer, prostate cancer and lung cancer cells, with weak inhibitory effect on HeLa cells. Neojiangyouaconitine has the ability to kill specific tumor cell lines and can be applied to the research on the mechanisms of related cancers such as breast cancer, prostate cancer and lung cancer .
    Neojiangyouaconitine
  • HY-111015A
    IRC-083927

    		Microtubule/Tubulin Cancer
    IRC-083927 is an orally effective tubulin inhibitor. IRC-083927 binds to the colchicine site on tubulin to inhibit its polymerization, thereby inducing G2-M phase cell cycle arrest in tumor cells. IRC-083927 significantly inhibits endothelial cell proliferation and in vitro angiogenesis, and exhibits remarkable antitumor activity. IRC-083927 can be widely applied in relevant studies on human cervical cancer, breast cancer, pancreatic cancer, prostate cancer, as well as small cell and non-small cell lung cancer .
    IRC-083927
  • HY-130451
    Misakimycin

    		Fungal Infection Cancer
    Misakimycin is a naphthoquinone compound. Misakimycin exhibits cytotoxicity against human melanoma, breast cancer and ovarian cancer cells. Misakimycin can be found in strains of the genus Pyrenochaetopsis (strain MSX63693). Misakimycin can be used in research related to melanoma, breast cancer and ovarian cancer .
    Misakimycin
  • HY-N18228
    Stauntoside Ⅱ

    		Others Cancer
    Stauntoside Ⅱ is a 14,15-secopregnane-type C21 steroidal glycoside found in the roots of Cynanchum stauntonii. Stauntoside Ⅱ does not exhibit cytotoxic activity against human colon, hepatoma, gastric, lung, and ovarian cancer cells .
    Stauntoside Ⅱ

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: